The post hoc analysis() presented at the meeting investigated the relationship between the kinetics of response and long-term outcomes in patients who responded to treatment with 200 mg Cimzia® every 2 weeks and MTX, as measured by ACR20 response or change in DAS28 of greater than or equal to 1.2 from baseline.
Early Week 6 responders had significantly higher ACR20, ACR50 and ACR70 responses at Week 52, compared to the later Week 12 responders [ACR20 83.1% versus 66.7%; ACR50 66.7% versus 34.5%; and ACR70 39.0% versus 16.1%, respectively (p < 0.001)]. Patients with an early ACR20 response at Week 6 also experienced significantly greater improvements in physical function (HAQ-DI) and pain relief (VAS), compared to later Week 12 responders, and early Week 6 Disease Activity Score (DAS28) responders reported significantly greater pain relief (p < 0.001).
Radiographic data presented from the RAPID 1* open-label extension study found the inhibition of progression of structural joint damage observed from baseline to Week 24 and Week 52 was maintained out to Week 100 in patients who completed treatment with Cimzia® and MTX. The mean change from baseline in modified total Sharp score (mTSS)(b) for the combined Cimzia® dose groups at Week 100 was 0.59.
In the same study rapid improvements in ACR(a) scores were sustained up to 100 weeks in patients maintained on open-label treatment with 400 mg Cimzia® every 2 weeks and MTX in the RAPID 1. ACR20 response rates at Week 100, in patients who completed treatment with Cimzia® were 68.2% and 69.5% for patients who originally received Cimzia® 200 mg or 400 mg every 2 weeks plus MTX, respectively. ACR50 response rates were 55.2% and 51.5% respectively. Similar results were also observed for DAS28, and patient reported outcomes such as physical function and health-related quality of life.
These and other Cimzia® data are available o
Copyright©2009 PR Newswire.
All rights reserved